Clinical Trial Update: A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for AK105 (anti-PD-1) in relapsed or refractory classic Hodgkin lymphoma completed phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)

Snippet

Sponsor: Akeso | Conditions: Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: COMPLETED